Trial Profile
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-Fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-Fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIME
- Sponsors Amgen
- 07 Jun 2022 Results (n=461) of an analysis assessing predictive score to identify patients who are likely to benefit from Panitumumab treatment between differential variables subgroups using data from three clinical studies: NCT00364013, NCT00339183 and NCT00113763 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2022 Results of an analysis (n=328) assessed the tumor heterogeneity in response to therapy presented at the 113th Annual Meeting of the American Association for Cancer Research
- 13 Apr 2022 Results (n=935) assessing age related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer using patient data from this trial presented at the 113th Annual Meeting of the American Association for Cancer Research